# Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

> **NCT01234337** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 537 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Placebo
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01234337
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-21
- **Primary completion:** 2014-05-12
- **Final completion:** 2017-10-20
- **Target enrollment:** 537 (ACTUAL)
- **Last updated:** 2018-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01234337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01234337, "Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01234337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*